RHX 317
Alternative Names: RHX-317Latest Information Update: 28 Nov 2025
At a glance
- Originator Rheos Medicines
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Small molecules; Urologics
- Mechanism of Action MALT1 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Psoriasis; Rheumatoid arthritis
- No development reported Graft-versus-host disease; Lupus nephritis
Most Recent Events
- 28 Nov 2025 No recent reports of development identified for preclinical development in Graft-versus-host-disease in USA
- 28 Nov 2025 No recent reports of development identified for preclinical development in Lupus-nephritis in USA
- 20 Jul 2022 Rheos Medicine files an IND application with the US FDA in US for Autoimmune and Inflammatory disorders prior to July 2022